Student | Tianjin University of Traditional Chinese Medicine | China
Dr. Yanan Yang is a researcher at Tianjin University of Traditional Chinese Medicine, recognized for her contributions at the intersection of gut microbiota, metabolic regulation, and cardiometabolic diseases. Her scholarly influence is demonstrated by 726 citations, 45 peer-reviewed publications, and an h-index of 14, underscoring her growing impact in biomedical and translational health research. Dr. Yang’s work spans gut microbiome dynamics, microbial metabolites, metabolic disorders, traditional Chinese medicine mechanisms, and multi-omics integration. She has contributed to high-visibility studies on acute coronary syndrome, cardiovascular disease mechanisms, type 2 diabetes regulation, and herbal-medicine-induced metabolic modulation. Her involvement in multi-center collaborations—including meta-analyses with large participant cohorts—reflects her ability to bridge clinical findings with microbiome-mediated insights. Dr. Yang’s publications highlight a consistent focus on understanding microbial signatures, therapeutic pathways, and host–microbe interactions to advance preventive and precision medicine. She has also engaged in studies evaluating herbal interventions such as Coptis chinensis, showcasing the integration of traditional medicine with modern biomedical evidence. With over 223 co-authors across her publication record, her collaborative networks extend nationally and internationally, supporting multidisciplinary innovation in gut–heart metabolic axis research. Dr. Yang’s ongoing contributions provide essential foundations for developing microbiome-based diagnostics, therapeutic strategies for metabolic diseases, and evidence-based applications of traditional Chinese medicine, reflecting her role as an emerging and influential scientist in her field.
Featured Publications
-
Wu, C., Zhao, Y., Zhang, Y., Yang, Y., Su, W., Yang, Y., Sun, L., Zhang, F., Yu, J., … (2022). Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates prediction of BBR’s cholesterol-lowering efficacy in patients. Journal of Advanced Research, 37, 197–208. Cited by: 78
-
Dong, C., Yang, Y., Wang, Y., Hu, X., Wang, Q., Gao, F., Sun, S., Liu, Q., Li, L., Liu, J., … (2023). Gut microbiota combined with metabolites reveals unique features of acute myocardial infarction compared with stable coronary artery disease. Journal of Advanced Research, 46, 101–112. Cited by: 74
-
Dong, C., Yu, J., Yang, Y., Zhang, F., Su, W., Fan, Q., Wu, C., & Wu, S. (2021). Berberine, a potential prebiotic to indirectly promote Akkermansia growth through stimulating gut mucin secretion. Biomedicine & Pharmacotherapy, 139, 111595. Cited by: 74
-
Yang, Y. N., Wang, Q. C., Xu, W., Yu, J., Zhang, H., & Wu, C. (2022). The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet-induced hyperlipidemia and stimulates liver LDLR expression. Biomedicine & Pharmacotherapy, 155, 113749. Cited by: 60
-
Xu, W., Yu, J., Yang, Y., Li, Z., Zhang, Y., Zhang, F., Wang, Q., Xie, Y., Zhao, B., & Wu, C. (2023). Strain-level screening of human gut microbes identifies Blautia producta as a new anti-hyperlipidemic probiotic. Gut Microbes, 15(1), 2228045. Cited by: 57